(a virtual meeting)
- How to increase clinical benefit in an unselected patient population treatment of cancer patients with immune checkpoint inhibitors?
- What patient selection strategies using biomarkers (e.g. PD-L1, MSIhigh) can be implemented early during clinical drug development to increase the response rate and possibly accelerated approval?
- Can one identify patient subsets/tumor types using large datasets early during the drug development cycle that are more likely to respond to therapy?
Senior Vice President, Biology
Dirk Brockstedt is Senior Vice President of Biology and has more than 20 years of experience in the fields of immunology and oncology originating with his PhD from the University of Kiel and Stanford University. Dirk joined RAPT Therapeutics in January 2018, bringing a wealth of experience in immunology at all stages of discovery, translational and clinical development. He joined RAPT from Aduro Biotech, where he served as Executive Vice President of Research and Development. Prior to Aduro, Dirk held positions of increasing responsibility within the immunology department of Cerus Corporation and at Aventis in the immunotherapy and anti-angiogenesis groups. Dr. Brockstedt co-authored over 40 scientific papers and is a named inventor on seven issued patents and several pending applications.
- Common use cases and applications
- Recognized challenges and potential solutions or alternatives
- Innovative platforms and how they’ve been used
Customer Solutions Manager
ImmunXperts (a Nexelis company)
Amin holds a Bachelor of Science degree in Biology from McGill University, a Graduate Diploma in Biotechnology & Genomics, and a Master of Science degree in Cell & Molecular Biology both from Concordia University.
Early in his career, Amin worked on the cell cycle genetics of the fungal pathogen Candida albicans, characterizing the role a protein plays in modulating response to the environment. His passion for entrepreneurship led him to a business development role in the personalized medicine field before joining the contract research industry to help bring safe and effective medical innovations to patients.
1:00pm – 2:00pm
- Relevance of in vivo tox models – Human vs animal: target expression levels and tissue distribution, TA affinity to a target * When is a surrogate molecule needed? – Immune system – healthy animals versus cancer patients *Safety related to the tumor lysis syndrome
- Use of in vitro models
- Starting dose selection for FIH studies: best approaches for different IO modalities
Chief Scientific Officer & Co-Founder
Elena Brin earned her Ph.D. in Pharmacology from Northwestern University in 2002. She studied tumor immune evasion, immune-modulatory properties of cytokines/ cytokine gene therapy at Canji, Inc. (Schering-Plough). Elena was part of the team that developed nadofaragene firadenovec which recently showed impressive phase III results in bladder cancer patients. She continued to work on cancer drug discovery at Maxim Pharmaceuticals (EpiCept), Ambrx, Pfizer and Polaris Pharmaceuticals leading teams and projects in targeted and Immuno-Oncology, contributing from an early discovery to an IND submission. Elena co-authored multiple peer-reviewed publications, presented at conferences and is a co-inventor on several patent applications. In August 2020, Elena co-founded Athae Bio, a biotechnology company that incorporates machine learning into drug discovery.
- Are current preclinical IO models lack predictive validity with limited value in translational oncology research?
- Do we have sufficient understanding of the interactions between human immune cells and tumors to develop preclinical in vivo models to enhance the predictability of IO models for improved translation?
- What criteria go into selecting the most suitable models for translational studies?
Senior Vice President R&D
Chan Whiting, Ph.D. is the SVP of R&D at Tempest Therapeutics. Chan has over 15 years of leadership in drug development in areas of inflammation, infectious diseases, autoimmunity and oncology. Prior to Tempest, Chan was Director and Head of Immune Monitoring and Biomarker Development at Aduro Biotech where she established key partnerships and brought in cutting edge technologies to support clinical development. Other prior experiences include leading target identification and validation programs for systems biology companies including Entelos, Inc. and Ingenuity Systems (Qiagen).
Chan received a B.S. degree in Biochemistry and a Ph.D. in Biochemistry and Immunology from UCLA. She completed postdoctoral studies at Stanford University.
4:15pm – 4:45pm
Closing Keynote & Address